Bavunalimab is a bispecific human monoclonal antibody that dually targets CTLA-4 and LAG-3 immune checkpoints. It is designed to activate T cells and is used in preclinical cancer immunotherapy research, including studies in NSG mouse models and in vitro T cell assays.